摘要
目的探讨奥氮平与利培酮对恢复期精神分裂症患者心理健康状况的影响。方法将40例精神分裂症患者随机分为两组，研究组21例，口服奥氮平治疗，对照组19例，口服利培酮治疗，观察12周。于治疗前及治疗12周末采用阳性与阴性症状量表评定临床疗效，于治疗12周末采用症状自评量表评定心理健康状况，并与国内正常成人常模进行对比分析。结果治疗12周末，研究组总有效率为90．47％，对照组为89．47％，两组疗效差异无显著性（P〉0．05）；两组症状自评量表总分、总均分、阳性项目数及阳性症状均分差异均无娃著性（P〉0．05）；研究组抑郁、焦虑及恐怖因子分显著低于对照组（P〈0．05或0．01），精神病性因子分显著高于正常成人常模（P〈0．05），总分、总均分、阳性项目数及阳性症状均分及其他冈子分与正常成人常模差异均无显著性（P〉0．05）。结论奥氮平与利培酮治疗精神分裂症总体疗效相当；但奥氮平改善患者抑郁、焦虑和恐怖症状方面优于利培酮，治疗后其心理健康状况接近正常人水平。
Objective To explore the effects of olanzapine versus risperidone on mental health status of convalescence schizophrenia. Methods Forty schizophrenics were randomized to research group （n= 21） taking orally olanzapine and control group （n=19） did risperidone for 12 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before treatment and at the end of the 12th week, mental health status was assessed with Symptom Checklist-90 （SCL-90） at the end of the 12th week and compared with national norm. Results At the end of the 12th week, the total effective rate was respectively 90. 47% in the research and 89. 47% in the control group, which showed no significant difference （P〉0.05）; there were no significant differences in the total, total mean scores, positive items and the mean score of positive symptoms between the two groups （P〉0.05） ; depression, anxiety and phobia scores of the SCL-90 were significantly lower in the research compared with control group （P〈0.05 or 0.01）, psychotic score was significantly higher with norm （P〈0.05）, and there were no significant differences in total, total mean score, positive items and the mean score of the positive symptoms between the research and norm （P〉0.05）. Conclusion Olanzapine has the therapeutic equivalence to risperidone in schizophrenia; but olanzapine has an advantage over risperidone in improving depression, anxiety and pho bia, after olanzapine treatment patient＇s mental health status approach health adult level.
出处
《临床心身疾病杂志》
CAS
2011年第1期7-8,11,共3页
Journal of Clinical Psychosomatic Diseases
